Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000633330 | SCV000754552 | uncertain significance | Li-Fraumeni syndrome | 2017-09-20 | criteria provided, single submitter | clinical testing | This variant has not been reported in the literature in individuals with TP53-related disease. ClinVar contains an entry for this variant (Variation ID: 161517). Experimental studies have shown that this missense change disrupts the transactivation activity of the TP53 protein (PMID: 12826609). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. This sequence change replaces arginine with isoleucine at codon 280 of the TP53 protein (p.Arg280Ile). The arginine residue is highly conserved and there is a moderate physicochemical difference between arginine and isoleucine. This variant is not present in population databases (ExAC no frequency). |
Myriad Genetics, |
RCV004019784 | SCV004930575 | likely pathogenic | Li-Fraumeni syndrome 1 | 2024-02-20 | criteria provided, single submitter | clinical testing | This variant is considered likely pathogenic. Functional studies indicate this variant impacts protein function [PMID: 29979965]. This variant is expected to disrupt protein structure [Myriad internal data]. |
Science for Life laboratory, |
RCV000149052 | SCV000088694 | unknown | Malignant tumor of prostate | no assertion criteria provided | not provided | Converted during submission to Uncertain significance. |